Detecting Heart Conditions Faster: The Case for Biomarkers-PLUS-AI | Dean Loizou, Prevencio

BY JESSICA DAMASSA Can artificial intelligence help prevent cardiovascular diseases? Biotech startup, Prevencio, has developed a proprietary panel of biomarkers that uses blood proteins and sophisticated AI algorithms to detect cardiovascular conditions like coronary and peripheral artery disease, aerotic stenosis, risk for stroke and more. Dean Loizou, Prevencio’s VP of Business Development, breaks down the process step-by-step and explains exactly how Prevencio reports its clinically viable scores to doctors. How does the AI fit into all this? We get to that too, plus the details around this startup’s plans for raising a B-round on the heels of this work with Bayer. Filmed at Bayer G4A Signing Day in Berlin, Germany, October 2019. The post Detecting Heart Conditions Faster: The Case for Biomarkers-PLUS-AI | Dean Loizou, Prevencio appeared first on The Health Care Blog.
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Tech Jessica DaMassa WTF Health Artificial intelligence Bayer G4A Signing Day Biotech Dean Loizou heart disease Prevencio Source Type: blogs

Related Links:

ConclusionCardiovascular morbidity was increased in patients with TA attending primary care services in the UK. Treatment with statins and anti ‐platelets in these patients was suboptimal.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
CONCLUSIONS: Multimorbid patients with ACS are at a greater risk for worse outcomes than their nonmultimorbid counterparts. Lack of consistent measurement makes interpretation of the impact of multimorbidity challenging and emphasizes the need for more research on multimorbidity's effects on postdischarge healthcare utilization. PMID: 32925234 [PubMed - as supplied by publisher]
Source: The Journal of Cardiovascular Nursing - Category: Nursing Authors: Tags: J Cardiovasc Nurs Source Type: research
Conclusions: Women with a history of HDP are at an increased risk of future CVD-related morbidity and mortality. Our study highlights the importance of life-long monitoring of cardiovascular risk factors in women with a history of HDP.Cardiology
Source: Cardiology - Category: Cardiology Source Type: research
In conclusion, careful monitoring of patients in the early stages of CKD would result in lower morbidity and mortality. These objectives can be achieved by implementing screening programs and early interventions. PMID: 32509001 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSIONS: There is currently insufficient evidence to determine the effectiveness or ineffectiveness of chelation therapy in improving clinical outcomes of people with atherosclerotic cardiovascular disease. More high-quality, randomised controlled trials are needed that assess the effects of chelation therapy on longevity and quality of life among people with atherosclerotic cardiovascular disease. PMID: 32367513 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Abstract Atherosclerosis (AS) as a chronic inflammatory disorder of the cardiovascular system, is one of the leading cause of ischemic heart disease, stroke and peripheral vascular disease. There is growing evidence on the role of innate and adaptive immunity in the pathogenesis of atherosclerosis. Interleukin-18 is one of the novel proinflammatory cytokines involved in the atherogenesis, atherosclerotic plaque instability and plaque rupture. In this review, we overview the findings of the preclinical and clinical studies about the role and mechanism of action of IL-18 in the pathogenesis of AS, which could offer ...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: Heterozygous FH is associated with increased risk for stroke, PAD and AoVC. Clinicians should take these non-CHD ASCVD aspects into consideration for optimal management of FH patients. PMID: 32096673 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Diabetes mellitus (DM) is a globally chronic condition that currently affects over 422 million people worldwide, a number that has been estimated to grow to 552 million by 2030 [1,2]. Saudi Arabia is one of the nations with the highest DM prevalence regionally and internationally [3]. Hypertension (HT) is more common in patients with diabetes than in those without diabetes [4,5]. The co-occurrence of HT has a substantial clinical effect of producing a poor outcome for patients with diabetes. Complications such as renal failure, stroke, heart disease, peripheral vascular disease, and mortality are the most adverse outcomes ...
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Original research Source Type: research
Publication date: Available online 24 February 2020Source: Pharmacology &TherapeuticsAuthor(s): Concetta Schiano, Giuditta Benincasa, Monica Franzese, Nunzia Della Mura, Katia Pane, Marco Salvatore, Claudio NapoliAbstractThe complex pathobiology underlying cardiovascular diseases (CVDs) has yet to be explained. Aberrant epigenetic changes may result from alterations in enzymatic activities, which are responsible for putting in and/or out the covalent groups, altering the epigenome and then modulating gene expression. The identification of novel individual epigenetic-sensitive trajectories at single cell level might pro...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
More News: Biotechnology | Blogging | Cardiology | Cardiovascular | Germany Health | Health | Health Management | Heart | Heart Disease | Heart Transplant | Peripheral Vascular Disease (PVD) | Stroke